Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q2 2026 · 10-Q
Revenue$114.44M$114.44M+11.4% vs Q2 2025 Net Income-$17.74M-$17.74MN/M vs Q2 2025 EPS Diluted-$0.60-$0.60N/M vs Q2 2025 Gross Profit$78,238,000+10.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived-$28,981,000N/M Free Cash Flowderived-$39,095,000N/M Margins · derivedGross margin68.4%−0.7 pt vs Q2 2025
Operating margin-15.3%−24.0 pt vs Q2 2025
Net margin-15.5%−26.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end